Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY22 results · Apr–Jun 2021
Gufic Biosciences reported revenue from operations of ₹250.76 crore (up 363.1% from Q1 FY21) and net profit of ₹31.21 crore for Q1 FY22 (Apr–Jun 2021), on a standalone basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 250.76 | 54.14 | +363.1% | 131.93 | +90.1% |
| Other income | 1.23 | 0.99 | +24.2% | 0.66 | +87.3% |
| Total income | 251.99 | 55.13 | +357.1% | 132.58 | +90.1% |
| Profit before tax | 41.54 | (5.11) | Turned profit | 17.05 | +143.7% |
| Net profit for the period | 31.21 | (3.75) | Turned profit | 12.87 | +142.5% |
| EPS, basic (₹) | 3.22 | (0.48) | not comparable | 1.33 | +142.1% |
| Net margin (%) | 12.4 | -6.9 | 9.8 |
Standalone
- Filed with BSE
- 12 Aug 2021, 11:48 IST
- Board meeting
- 11 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE